Review



zikv  (Native Antigen Inc)


Bioz Verified Symbol Native Antigen Inc is a verified supplier
Bioz Manufacturer Symbol Native Antigen Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Native Antigen Inc zikv
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Zikv, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pmc12714709-345-1-6
    Average 92 stars, based on 10 article reviews
    zikv - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates"

    Article Title: Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates

    Journal: Nature Communications

    doi: 10.1038/s41467-025-66073-4

    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus (ZIKV). C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and ZIKV NS1-specific antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Figure Legend Snippet: a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus (ZIKV). C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and ZIKV NS1-specific antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .

    Techniques Used: Virus, Infection

    a Blood plasma ZIKV RNA kinetics after challenge of Sham ( n = 4) or YF-ZIK ( n = 6) immunized macaques. Circles represent individual animals; solid lines with shaded area, mean ± SEM. b ZIKV NS1-specific antibody levels in the blood plasma after ZIKV challenge. Data presented as median ± IQR. Data analysed by two-way variance (ANOVA) with Tukey multi-comparison tests. c ZIKV-specific SNT 50 NAbs in Sham and YF-ZIK immunized macaques after ZIKV challenge. Colour-coded lines represent individual animals. LLOD, lower limit of detection.
    Figure Legend Snippet: a Blood plasma ZIKV RNA kinetics after challenge of Sham ( n = 4) or YF-ZIK ( n = 6) immunized macaques. Circles represent individual animals; solid lines with shaded area, mean ± SEM. b ZIKV NS1-specific antibody levels in the blood plasma after ZIKV challenge. Data presented as median ± IQR. Data analysed by two-way variance (ANOVA) with Tukey multi-comparison tests. c ZIKV-specific SNT 50 NAbs in Sham and YF-ZIK immunized macaques after ZIKV challenge. Colour-coded lines represent individual animals. LLOD, lower limit of detection.

    Techniques Used: Clinical Proteomics, Comparison

    Related Articles

    Recombinant:

    Article Title: A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy
    Article Snippet: .. Recombinant ZIKV NS1 protein , Native Antigen , Cat # ZIKVSU-NS1. ..

    Produced:

    Article Title: Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine
    Article Snippet: .. Expression system AntiHuman_IgG SouthernBiotech 9042–01 Mouse ZIKV_PRV.WT_E.dom12 Produced in-house NA Drosophila S2-insect cells ZIKV_PRV.WT_E.dom3 Produced in-house NA Expi293F-human cells ZIKV_Sur_NS1 The Native Antigen Company ZIKVSU-NS1–100 HEK293-human cells ZIKV_FP13_NS1 R&D Systems 9450-ZK-100 HEK293-human cells ZIKV_Sur_E The Native Antigen Company ZIKVSU-ENV-100 HEK293-human cells ZIKV_PRV.WT_E Produced in-house NA Drosophila S2-insect cells ZIKV_PRV.FL4_E Produced in-house NA Drosophila S2-insect cells ZIKV_ConAf_E Produced in-house NA Drosophila S2-insect cells JEV_SA14_E Produced in-house NA Drosophila S2-insect cells JEV_SA14_NS1 The Native Antigen Company JEV-NS1–100 HEK293-human cells YFV_17D_E Produced in-house NA Drosophila S2-insect cells YFV_17D_NS1 The Native Antigen Company YFV-NS1–100 HEK293-human cells DENV.4_Dom81_NS1 The Native Antigen Company DENV4-NS1–100 HEK293-human cells DENV.4_Dom81_E The Native Antigen Company DENV4-ENV-100 HEK293-human cells DENV.3_PR98_NS1 Cal Bioreagents A256 Baculovirus-insect cells DENV.3_PR98_E Cal Bioreagents A252 Baculovirus-insect cells DENV.2_Ind01_NS1 Cal Bioreagents A255 Baculovirus-insect cells DENV.2_Ind01_E Cal Bioreagents A251 Baculovirus-insect cells DENV.1_VN07_NS1 Cal Bioreagents A254 Baculovirus-insect cells DENV.1_VN07_E Cal Bioreagents A250 Baculovirus-insect cells WNV_NY99_E The Native Antigen Company REC31614–100 HEK293-human cells WNV_NY99_NS1 The Native Antigen Company WNV-NS1–100 HEK293-human cells TBEV_Neu_NS1 The Native Antigen Company TBEV-NS1–100 HEK293-human cells CHIKV_NA_E1 The Native Antigen Company CHIKV-E1–100 HEK293-human cells *CHIKV, chikungunya virus; DENV, dengue virus; JEV, Japanese encephalitis virus; TBEV, tickborne encephalitis virus; YFV, yellow fever virus; WNV, West Nile virus; ZIKV, Zika virus. ..

    Virus:

    Article Title: Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine
    Article Snippet: .. Expression system AntiHuman_IgG SouthernBiotech 9042–01 Mouse ZIKV_PRV.WT_E.dom12 Produced in-house NA Drosophila S2-insect cells ZIKV_PRV.WT_E.dom3 Produced in-house NA Expi293F-human cells ZIKV_Sur_NS1 The Native Antigen Company ZIKVSU-NS1–100 HEK293-human cells ZIKV_FP13_NS1 R&D Systems 9450-ZK-100 HEK293-human cells ZIKV_Sur_E The Native Antigen Company ZIKVSU-ENV-100 HEK293-human cells ZIKV_PRV.WT_E Produced in-house NA Drosophila S2-insect cells ZIKV_PRV.FL4_E Produced in-house NA Drosophila S2-insect cells ZIKV_ConAf_E Produced in-house NA Drosophila S2-insect cells JEV_SA14_E Produced in-house NA Drosophila S2-insect cells JEV_SA14_NS1 The Native Antigen Company JEV-NS1–100 HEK293-human cells YFV_17D_E Produced in-house NA Drosophila S2-insect cells YFV_17D_NS1 The Native Antigen Company YFV-NS1–100 HEK293-human cells DENV.4_Dom81_NS1 The Native Antigen Company DENV4-NS1–100 HEK293-human cells DENV.4_Dom81_E The Native Antigen Company DENV4-ENV-100 HEK293-human cells DENV.3_PR98_NS1 Cal Bioreagents A256 Baculovirus-insect cells DENV.3_PR98_E Cal Bioreagents A252 Baculovirus-insect cells DENV.2_Ind01_NS1 Cal Bioreagents A255 Baculovirus-insect cells DENV.2_Ind01_E Cal Bioreagents A251 Baculovirus-insect cells DENV.1_VN07_NS1 Cal Bioreagents A254 Baculovirus-insect cells DENV.1_VN07_E Cal Bioreagents A250 Baculovirus-insect cells WNV_NY99_E The Native Antigen Company REC31614–100 HEK293-human cells WNV_NY99_NS1 The Native Antigen Company WNV-NS1–100 HEK293-human cells TBEV_Neu_NS1 The Native Antigen Company TBEV-NS1–100 HEK293-human cells CHIKV_NA_E1 The Native Antigen Company CHIKV-E1–100 HEK293-human cells *CHIKV, chikungunya virus; DENV, dengue virus; JEV, Japanese encephalitis virus; TBEV, tickborne encephalitis virus; YFV, yellow fever virus; WNV, West Nile virus; ZIKV, Zika virus. ..



    Similar Products

    zikv  (Native Antigen Inc)
    92
    Native Antigen Inc zikv
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Zikv, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pmc12714709-345-1-6
    Average 92 stars, based on 1 article reviews
    zikv - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    pbs  (Native Antigen Inc)
    92
    Native Antigen Inc pbs
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Pbs, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pm41720296-98-29-30
    Average 92 stars, based on 1 article reviews
    pbs - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    zikv rns1  (Native Antigen Inc)
    92
    Native Antigen Inc zikv rns1
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Zikv Rns1, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pm41720296-153-22-24
    Average 92 stars, based on 1 article reviews
    zikv rns1 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    zika virus ns1 protein (suriname strain)  (Native Antigen Inc)
    92
    Native Antigen Inc zika virus ns1 protein (suriname strain)
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Zika Virus Ns1 Protein (Suriname Strain), supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/custom%40zikvsu-ns1%4040333188
    Average 92 stars, based on 1 article reviews
    zika virus ns1 protein (suriname strain) - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    zikvsu ns1  (Native Antigen Inc)
    92
    Native Antigen Inc zikvsu ns1
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Zikvsu Ns1, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pmc10562857__mmc1-13-24-20
    Average 92 stars, based on 1 article reviews
    zikvsu ns1 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    cells zikv sur ns1  (Native Antigen Inc)
    92
    Native Antigen Inc cells zikv sur ns1
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Cells Zikv Sur Ns1, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pmc10562857__mmc1-13-18-20
    Average 92 stars, based on 1 article reviews
    cells zikv sur ns1 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    igg antibodies against zikv  (Native Antigen Inc)
    92
    Native Antigen Inc igg antibodies against zikv
    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus <t>(ZIKV).</t> C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and <t>ZIKV</t> <t>NS1-specific</t> antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .
    Igg Antibodies Against Zikv, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zikvsu+ns1/Zika+Virus+NS1+Protein+(Suriname+Strain)/pmc09271056-86-6-10
    Average 92 stars, based on 1 article reviews
    igg antibodies against zikv - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus (ZIKV). C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and ZIKV NS1-specific antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .

    Journal: Nature Communications

    Article Title: Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates

    doi: 10.1038/s41467-025-66073-4

    Figure Lengend Snippet: a Schematic of YF17D and YF17D-based Zika vaccine candidate YF-ZIK. The antigenic surface glycoproteins and the capsid anchor of YF17D were replaced with a prototypic Asian lineage Zika virus (ZIKV). C core, NS non-structural protein, UTR untranslated region. b Schematic of non-human primates (NHPs) vaccination and challenge study. Rhesus macaques ( Macaca mulatta ) were immunized s.c. twice (at day 0 and day 28) with 10 5 PFU of YF-ZIK ( n = 6) or medium (sham; n = 4). At day 56, all macaques were i.d. infected with 10 5 PFU of ZIKV DR/2016/PD1 strain. Weight and temperature changes were monitored daily until day 70. Blood was sampled weekly for hematology and serology (NAb) analyses. Whole blood was collected for transcriptional analysis after prime (at day 0, 2, 7), boost (at day 28, 30, 35), and challenge (at day 56, 57, 60); and PBMCs to assess CMI responses by ICS (at day 42). Viremia and ZIKV NS1-specific antibody levels after challenge were quantified until day 70. Created in BioRender. Ma, J. (2025) https://BioRender.com/0jgftwr .

    Article Snippet: The ZIKV (Suriname) NS1 recombinant protein (The Native antigen company, cat. no. ZIKVSU-NS1-100) was used at a concentration of 1 μg/ml in Dulbecco’s phosphate-buffered saline (DPBS, Gibco) to coat 96-well microplates overnight at room temperature (RT).

    Techniques: Virus, Infection

    a Blood plasma ZIKV RNA kinetics after challenge of Sham ( n = 4) or YF-ZIK ( n = 6) immunized macaques. Circles represent individual animals; solid lines with shaded area, mean ± SEM. b ZIKV NS1-specific antibody levels in the blood plasma after ZIKV challenge. Data presented as median ± IQR. Data analysed by two-way variance (ANOVA) with Tukey multi-comparison tests. c ZIKV-specific SNT 50 NAbs in Sham and YF-ZIK immunized macaques after ZIKV challenge. Colour-coded lines represent individual animals. LLOD, lower limit of detection.

    Journal: Nature Communications

    Article Title: Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates

    doi: 10.1038/s41467-025-66073-4

    Figure Lengend Snippet: a Blood plasma ZIKV RNA kinetics after challenge of Sham ( n = 4) or YF-ZIK ( n = 6) immunized macaques. Circles represent individual animals; solid lines with shaded area, mean ± SEM. b ZIKV NS1-specific antibody levels in the blood plasma after ZIKV challenge. Data presented as median ± IQR. Data analysed by two-way variance (ANOVA) with Tukey multi-comparison tests. c ZIKV-specific SNT 50 NAbs in Sham and YF-ZIK immunized macaques after ZIKV challenge. Colour-coded lines represent individual animals. LLOD, lower limit of detection.

    Article Snippet: The ZIKV (Suriname) NS1 recombinant protein (The Native antigen company, cat. no. ZIKVSU-NS1-100) was used at a concentration of 1 μg/ml in Dulbecco’s phosphate-buffered saline (DPBS, Gibco) to coat 96-well microplates overnight at room temperature (RT).

    Techniques: Clinical Proteomics, Comparison